GigaGen Initiates Phase 1 Trial, Administers Initial Dose of GIGA-564 Anti-CTLA-4 Drug Candidate to Advanced Solid Tumor Patient.

GRI Bio Shows Promising Preclinical Results: Lead Candidate GRI-0621 Reduces Key Inflammatory and Fibrotic Factors in Idiopathic Pulmonary Fibrosis (IPF).

Rila Therapeutics Begins Dosing First Group in Phase 1 Trial of RLA-23174, an Innovative HIPK2 Allosteric Inhibitor, to Treat Chronic Kidney Disease and Fibrosis.

Innovent announces that the NMPA of China has accepted the NDA for IBI311, an IGF-1R antibody, for the treatment of Thyroid Eye Disease.

Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., together with Alvotech, have declared the launch of SIMLANDI (adalimumab-ryvk) injection within the United States.

Arrowhead Pharmaceuticals Unveils New Clinical Data Indicating Significant Gene Knockdown by ARO-RAGE in Asthma Patients.

Nature Communications Releases Key Data Showing Effectiveness and Safety of CSL and Arcturus Therapeutics’ COVID-19 Vaccine.

Atara Biotherapeutics Files Biologics License Application for Tab-cel® to Treat EBV Positive Post-Transplant Lymphoproliferative Disease with the FDA.

New Phase 2a trial data shows Endeavor BioMedicinesa’ ENV-101 enhanced lung performance and reversed critical indicators of lung fibrosis in idiopathic pulmonary fibrosis patients.

Experimental Seladelpar Shows Notable Advancements in Liver Disease and Alleviates Itching in Primary Biliary Cholangitis.

The SUPERNOVA Phase III trial for the long-acting antibody sipavibart successfully met its primary goals in preventing COVID-19 among immunocompromised patients.

Recludix Pharma Shares Data Showing Oral STAT3 Inhibitors Offer Unique Efficacy and Safety in Th17-Driven Skin Inflammation Preclinical Models during Oral Session at SID Annual Meeting.